Exact Sciences Corporation (NASDAQ:EXAS) is in the good books of brokerage firms across North America with the stock receiving an average ‘hold’ rating from thirteen ratings firms.
Ratings indicate that seven analysts have given a ‘hold’ recommendation for Exact Sciences Corporation (NASDAQ:EXAS) stocks while six have assigned a ‘buy’ recommendation to the company. The stock has been at the centre point of a number of research reports including those from Canaccord Genuity, Zacks Investment Research, Jefferies Group, and BTIG Research among others.
If we look at each of these analysts and their recommendations, Canaccord Genuity has given a ‘buy’ rating for EXAS with a target price set for $24. Zacks Investment Research also gave shares of Exact Sciences Corporation a “buy” rating and set a $16.00 price objective on the stock in a research report on Tuesday, December 6th. Robert W. Baird gave a ‘buy’ rating with a target price set to $22.00. Jefferies Group raised their price objective on shares of Exact Sciences Corporation from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday, October 4th. Finally, BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Exact Sciences Corporation in a research report on Sunday, January 8th.
Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, October 26th, 2016 wherein it reported ($0.36) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.06. The firm had revenue of $28.10 million for the quarter, compared to analysts’ expectations of $25.24 million. Exact Sciences Corporation had a negative net margin of 216.45% and a negative return on equity of 55.44%. The business’s quarterly revenue was up 122.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.45) EPS. Equities analysts expect that Exact Sciences Corporation will post ($1.71) EPS for the current fiscal year.
A number of large investors including Vanguard Group Inc., Gilder Gagnon Howe & Co. LLC, BlackRock Institutional Trust Company N.A., EverPoint Asset Management LLC and BlackRock Fund Advisors have raised their stake in Exact Sciences Corporation.